Skip to content
DataLookout
Menu

NCT07830329

Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below.

  1. Notable Recruitment opened
    • Start date changed from estimate of Oct 30, 2026 to Oct 29, 2026
    • Study sites: 0 to 1
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Percent change in total Abscess and inflammatory Nodule (AN) count
Timeframe: From baseline to week 52

Secondary (13)

Percent change in body weight
Achieving HiSCR50 (≥50% reduction from baseline in total AN counts with no increase in abscess count and no increase in draining tunnel count)
Absolute change in weekly average Skin Pain Numeric Rating Scale (NRS)
Percent change in weekly average Skin Pain NRS
Achieving ≥3-point reduction in weekly average Skin Pain NRS
Show 8 moreShow less
Absolute change in Dermatology Life Quality Index (DLQI)
Achieving minimum clinically important difference (reduction of ≥4 points from baseline score) in the DLQI total score
Absolute change in high-sensitivity C-Reactive Protein (hsCRP)
Percent change in hsCRP
Concentrations of olatorepatide
Occurrence of Anti-Drug Antibodies (ADAs) to olatorepatide
Magnitude of ADAs to olatorepatide
Occurrence of Treatment-Emergent Adverse Events (TEAEs)

Arms and interventions

OlatorepatideExperimental
PlaceboPlacebo comparator

Drugs: Olatorepatide, Placebo

Sites

1 site in 1 country

  • Equity Medical, LLCThe Bronx, New York, United States